By
Trending Posts
Pfizer Expands Deal to $610M, AI Drug Discovery…
Boston – Jan 7, 2025 Strengthening AI-Driven Innovation in Small Molecules and ADCs Pfizer has expanded its partnership…
Terray’s AI-Driven Drug Discovery Platform Secures Collaboration with…
Boston – Dec 17, 2024 Strategic Expansion Following $120M Series B Terray Therapeutics is closing the year with…
Unlearn AI’s Breakthroughs in AI-Driven Clinical Development: 2024…
San Francisco – December 12, 2024 Unlearn AI has emerged as a leader in AI-powered clinical trial innovation,…
How Unlearn AI Is Increasing the Efficiency of…
December 11, 2024 Enhanced TwinRCT™ 3.0 Unlearn® has introduced an upgraded version of its AI-driven TwinRCT™ solution—TwinRCT 3.0,…
Relation Therapeutics, NVIDIA-Backed AI-Biotech, and GSK Announce Strategic…
London, UK – December 10, 2024 Relation, a leader in computational and experimental drug discovery, has announced two…
Recursion Reports Promising Interim Data for AI-Designed CDK7…
Salt Lake City – December 9, 2024 Recursion (Nasdaq: RXRX), a leader in AI-powered drug discovery, has released…
Recursion Doses First Patient in Phase 1/2 Trial…
Recursion (NASDAQ: RXRX), a cutting-edge clinical-stage TechBio company, has announced the successful dosing of the first patient in…
AI Drug Discovery Leaders Recursion and Exscientia Merge…
Recursion and Exscientia, two trailblazers in AI-driven drug discovery, have officially merged to form a technology-powered platform aimed…
NVIDIA Expands AI-Driven Drug Discovery with BioNeMo Framework
November 18, 2024 NVIDIA has launched a major initiative to scale AI-powered drug discovery through the open-source BioNeMo…
Trending Posts
Latest Stories
Why Is Eli Lilly’s 2025 Outlook Soaring Despite Orforglipron’s Late-Stage Trial Falling Short?
Key Highlights: Strong Sales Growth and Raising GuidanceEli Lilly posted impressive Q2 2025 earnings surpassing…
Why Could Novartis’ Ianalumab, With Dual Mechanism of B-Cell Depletion and BAFF-R Inhibition, Revolutionize Treatment for Sjögren’s Disease?
Key Highlights: Positive Phase III Results Confirm Efficacy in Sjögren’s DiseaseThe NEPTUNUS-1 (275 patients) and…
Can AstraZeneca’s $50 Billion U.S. Investment and Drug Price Cuts Signal a New Era of Affordable Innovation and Domestic Manufacturing?
Key Highlights: Strategic Response to U.S. Pricing PressuresAstraZeneca CEO Pascal Soriot announced proactive proposals for…
How Google Med-Gemini’s “Basilar Ganglia” AI Hallucination Signal a Wake-Up Call for Safer AI in Medical Diagnostics?
Key Highlights: AI Hallucination: The “Basilar Ganglia” ErrorGoogle’s Med-Gemini suite, designed to summarize health data…
Gallery
